Genmab A/S (OTCMKTS:GNMSF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. began coverage on shares of Genmab A/S in a research note on Tuesday, June 21st. They issued a “neutral” rating for the company.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of Genmab A/S (OTCMKTS:GNMSF) remained flat at $158.25 during mid-day trading on Tuesday. The company’s 50 day moving average is $162.19 and its 200 day moving average is $161.78. The stock has a market cap of $9.47 billion, a PE ratio of 94.70 and a beta of 0.76. Genmab A/S has a 52-week low of $93.25 and a 52-week high of $183.00.

Get a free copy of the Zacks research report on Genmab A/S (GNMSF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with's FREE daily email newsletter.